RTRX Retrophin, Inc.

20.67
+0.1  (0.49%)
Previous Close 20.57
Open 20.55
Price To book 2.52
Market Cap 779.92M
Shares 37,732,000
Volume 262,175
Short Ratio 13.94
Av. Daily Volume 393,948

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in coming months - as of January 9, 2017.
RE-024
Pantothenate kinase-associated neurodegeneration (PKAN)
Efficacy trial to be initiated 2H 2016
RE-024
Pantothenate kinase-associated neurodegeneration (PKAN)
NDA filing due 2017
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
Approved Mar 18 2015
Cholbam
Rare Bile Acid Synthesis Disorders
Phase 2 top-line data released September 8, 2016. Further data released 19 November, 2016 at the American Society of Nephrology (ASN) Kidney Week.
Sparsentan (DUET)
Focal segmental glomerulosclerosis (FSGS)

Latest News

  1. Accused fraudster Shkreli's co-defendant Greebel blasts him as a serial liar in separate trial bid
  2. Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results
  3. Retrophin Appoints William Rote Senior Vice President, Research and Development
  4. Accused fraudster Martin Shkreli involved in new company seeking $1 million in debt offering
  5. RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  6. Retrophin Provides Corporate Update and 2017 Preview
  7. 'Pharma bro' Shkreli suspended from Twitter for harassment
  8. Retrophin Appoints Elizabeth Reed General Counsel
  9. Retrophin Appoints Elizabeth Reed General Counsel
  10. Retrophin to Present at the 35th Annual J.P. Morgan Healthcare Conference
  11. Biotech Stocks to Watch After Senate Drug Report
  12. The Senate just released a massive report on drug pricing — here's what you need to know
  13. JMP Conducts Retrophin Survey To Understand Story
  14. Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : December 13, 2016
  15. Is CF Corp (CFCO) A Good Stock To Buy According To Hedge Funds?
  16. ETFs with exposure to Retrophin, Inc. : December 2, 2016
  17. Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : December 1, 2016
  18. Retrophin to Present at the BMO Capital Markets Healthcare Conference
  19. Is Retrophin Inc (RTRX) A Good Stock To Buy?
  20. Ligand's Partner Retrophin Provides New Data on Sparsentan